# AxoGen

Type: Company (AXGN)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/axogen
Canonical HTML page: https://getbiobrief.com/entity/axogen

## Recent coverage (2 stories)

### DAFNA Capital Trims Axogen Stake Following 71% Rally and 20% Revenue Growth
2026-03-22 04:25:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, a move that follows a significant 71% surge in the company's stock price. Despite the trim, Axogen remains a significant holding for the fund as the company continues to see 20% revenue growth driven by its peripheral nerve repair portfolio.
Full story: https://getbiobrief.com/story/dafna-capital-trims-axogen-stake-71-surge

### Wells Fargo Upgrades AxoGen to Strong-Buy as Nerve Repair Market Gains Momentum
2026-02-21 01:12:15 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wells Fargo has upgraded AxoGen (NASDAQ: AXGN) to a 'Strong-Buy' rating, reflecting growing institutional confidence in the company's leadership in peripheral nerve repair. The upgrade follows a significant price target increase from Jefferies and a reaffirmed 'Market Outperform' rating from Citigroup.
Full story: https://getbiobrief.com/story/axogen-wells-fargo-upgrade-nerve-repair-market

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.